Pretreatement with #P2Y12 inhibitors in #STEMI patients! An analysis of 1,116 patients in the Bern-PCI registry demonstrated that pretreatment did not impact #MACE, stent thrombosis, #bleeding or procedural aspects 🫀 https://t.co/XZLh6gWxRS
#JACCINT#P2Y12i#PCI
The #ScatterMatters movement continues at in South Carolina! We are proud to protect the entire team at @RoperStFrancis with 2 new #EggNest Radiation Protection Systems, because everyone in the room deserves protection from scatter radiation ☢.
#EggMedical #ProtectEveryoneInEveryCase
So very excited to share our latest paper on conduction system pacing torque transfer with different leads!
Thank you to @shivkumarmd and editors for help to publish our findings.
@Anand_Ganesan1
https://t.co/4a2OiOnlaw
🙌Amazing results from the PARTNER 3 trial🙌 TAVR with Sapien 3 valve is superior to surgery in low-risk patients with severe aortic stenosis, even after 2 years of follow-up. This confirms the durability and safety of this minimally invasive procedure. #TAVR#Sapien3#PARTNER3
👏Good news for AL amyloidosis patients👏 Isatuximab, a drug approved for multiple myeloma, can also treat relapsd refractory AL #amyloidosis, according to a new study. This could be a new option for those who don’t respond to standard therapy. #isatuximab#SWOG#ASH2023
🚨Breaking News🚨
New study shows that semaglutide reduces cardiovascular risk in obesity without diabetes¹. This could be a game-changer for patients with preexisting heart disease and excess weight. #cardiology#obesity#semaglutide#STEP2
Young patient with new onset heart failure, presentation in cardiogenic shock (SCAI D), flu-like symptoms for 7 days, flu A+.
What is your treatment preference?
#flu#fluseason#heartfailure#cardiotwitter
A rare case of IgG4-RD–associated myocardial mass causing severe aortic incompetence in a 53 y/o ♀ ➡️ successfully treated with mechanical aortic prosthesis and corticosteroids. https://t.co/FXq8L9hoPY
#JACCCaseReports#SAVR#CardioTwitter
#COVID19 positive donors are being used for heart transplant, with rates similar to HepC donors (7.9% vs 7.1% in 2022).
https://t.co/yAJmICZVQ8
We need standardized protocols for COVID+ donors to make it the next frontier for donor pool expansion.
#ISHLT#CardioTwitter#UNOS
Rivaroxaban was associated with reduced risk of recurrent #VTE and comparable risks of bleeding and mortality versus LMWH in patients with active cancer in the real-world OSCAR-US study. https://t.co/bEjUro3PWi
#JACCCardioOnc#CardioOnc#cvCoag#Rivaroxaban#CardioTwitter